Study of RP1 Monotherapy and RP1 in Combination With Nivolumab (IGNYTE)
Trial details
- Registry ID
- NCT03767348
- Phase
- Phase 2
Drug identity checked against registry records
Also recorded as Genetically modified herpes simplex type 1 virus
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Study of RP1 Monotherapy and RP1 in Combination With Nivolumab (IGNYTE)NCT03767348 | Replimune, Inc. | Phase 2 | Active not recruiting | 2028-06Estimated |
| Study Evaluating Cemiplimab Alone and Combined With RP1 in Treating Advanced Squamous Skin CancerNCT04050436 | Replimune, Inc. | Phase 2 | Active not recruiting | 2025-09Estimated |
| No regulatory events match this view.This does not mean no FDA events have occurred. |